A study to determine molecular understanding of patient and treatment characteristics in patients with R/R LBCL treated with axicabtagene ciloleucel (axi-cel)
Latest Information Update: 18 Jan 2024
At a glance
- Drugs Axicabtagene ciloleucel (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Pharmacodynamics
Most Recent Events
- 17 Jan 2024 New trial record
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition